Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 17

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 17
---
 )

    —

    —

    Net loss

    (95,496
    )

    (188,917
    )

    (142,181
    )

    Net loss per share - basic
     
    $
    (1.02
    )
     
    $
    (2.37
    )
     
    $
    (2.17
    )

    Net loss per share - diluted
     
    $
    (1.02
    )
     
    $
    (2.37
    )
     
    $
    (2.17
    )

    Weighted-average number of common shares used in net loss per share - basic

    93,234,195

    79,773,004

    65,466,773

    Weighted-average number of common shares used in net loss per share - diluted

    93,234,195

    79,773,004

    65,466,773

The accompanying notes are an integral part of these financial statements.

F-7

Day One Biopharmaceuticals, Inc. 

Statements of Comprehensive Loss

(in thousands)

    Year Ended December 31,

    2024

    2023

    2022

    Net loss
     
    $
    (95,496
    )
     
    $
    (188,917
    )
     
    $
    (142,181
    )

    Other comprehensive income:

    Unrealized gain (loss) on available-for-sale securities

    75

    80

    (71
    )

    Total comprehensive loss
     
    $
    (95,421
    )
     
    $
    (188,837
    )
     
    $
    (142,252
    )

The accompanying notes are an integral part of these financial statements.

F-8

Day One Biopharmaceuticals, Inc. 

Statements of Stockholders’ Equity 

(in thousands, except share amounts)

    Common Stock

    AdditionalPaid-In

    Accumulated Other

    Accumulated

    Stockholders' Equity/Members'

    Shares

    Amount

    Capital

    Comprehensive Loss

    Deficit

    (Deficit)

    Balance at December 31, 2021

    61,952,292

    $
    6

    $
    408,629

    $
    —

    $
    (127,487
    )